Cardiovascular pharmacology: A look back and a glimpse into the future

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 1, Issue 1, 2015, Pages 7-9

  Braunwald, Eugene ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CHLORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPHEDRINE; EPINEPHRINE; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; MERALLURIDE; MICRORNA; MINERALOCORTICOID ANTAGONIST; MONOCLONAL ANTIBODY; PENICILLIN DERIVATIVE; PROPROTEIN CONVERTASE 9; QUINIDINE; SACUBITRIL PLUS VALSARTAN; SALICYLIC ACID DERIVATIVE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; WARFARIN;

ANGINA PECTORIS; BACTERIAL ENDOCARDITIS; BRADYCARDIA; CARDIOVASCULAR DISEASE; DRUG BLOOD LEVEL; EDITORIAL; GENETIC VARIABILITY; HEART BLOCK; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; MYOPATHY; PERSONALIZED MEDICINE; PHARMACOGENETICS; RHEUMATIC FEVER; TACHYCARDIA;

EID: 84927520149     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvu002     Document Type: Editorial

References (15)

1. Novello FC, Sprague JM. Benzothiadiazine dioxides as novel diuretics. J AmChem Soc 1957;79:2028-2029.
2. Kagawa CM, Sturtevant FM, van Arman CG. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. J Pharm Exp Ther 1959;126:123-130.
3. Black JW, Stephenson JS. Pharmacology of a new adrenergic beta-receptor-blocking compound (nethalide). Lancet 1962;280:311-314.
4. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensinconverting enzyme: new class of orally active antihypertensive agents. Science 1977;196:441-444.
5. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl- coenzyme A reductase by ML-236A and ML-236B fungal metabolites having hypocholesterolemic activity. FEBS Letters 1976;72:323-326.
6. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-1266.
7. Novartis International AG - press release, March 31, 2014 - "PARADIGM-HF TRIAL of Novartis LCZ696 for chronic heart failure closes early based on strength of interim results".
8. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ. Prospective comparison of A[EREH.J]NI with A[EREH.J]B on Management of heart failure with preserved ejection fraction (PARAMOUNT) Investigators. The angiotensin-receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-1395.
9. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrex M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366: 1108-1118.
10. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, MaciasW, Braunwald E, Sabatine MS. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.
11. The International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-764.
12. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008;359:789-799.
13. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved b1-adrenergic receptor motif alters cardiac function and b-blocker response in human heart failure. Proc Natl Acad Sci USA 2006;103:11288-11293.
14. Krutzfeldt J1, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with antagomirs. Nature 2005;438:685-689.
15. Wahlquist C, Jeong D, Rojas-Munoz A, Kho C, Lee A, Mitsuyama S, van Mil A, Park WJ, Sluijter JPG, Doevendans PAF, Hajjar RJ, Mercola M. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014;508: 531-535.